Overview

Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of Globalagliatin Hydrochloride (SY-004) after Multiple Ascending Doses in patients with Type 2 Diabetes Mellitus (T2DM).
Phase:
Phase 1
Details
Lead Sponsor:
Yabao Pharmaceutical Group